生存素
癌症研究
细胞凋亡
凋亡抑制因子
化疗
癌症
医学
生物
程序性细胞死亡
内科学
生物化学
作者
Sree Karani Kondapuram,Hema Kasthuri Ramachandran,Hemant Arya,Mohane Selvaraj Coumar
出处
期刊:Life Sciences
[Elsevier]
日期:2023-11-12
卷期号:335: 122260-122260
被引量:7
标识
DOI:10.1016/j.lfs.2023.122260
摘要
Survivin is a member of the family of inhibitors of apoptosis proteins (IAPs). It is involved in the normal mitotic process and acts as an anti-apoptotic molecule. While terminally differentiated normal tissues lack survivin, several human malignancies have significant protein levels. Resistance to chemotherapy and radiation in tumor cells is associated with survivin expression. Decreased tumor development, apoptosis, and increased sensitivity to chemotherapy and radiation are all effects of downregulating survivin expression or activity. As a prospective cancer treatment, small molecules targeting the transcription and translation of survivin and molecules that can directly bind with the survivin are being explored both in pre-clinical and clinics. Pre-clinical investigations have found and demonstrated the effectiveness of several small-molecule survivin inhibitors. Unfortunately, these inhibitors have also been shown to have off-target effects, which could limit their clinical utility. In addition to small molecules, several survivin peptide vaccines are currently under development. These vaccines are designed to elicit a cytotoxic T-cell response against survivin, which could lead to the destruction of tumor cells expressing survivin. Some survivin-based vaccines are advancing through Phase II clinical studies. Overall, survivin is a promising cancer drug target. However, challenges still need to be addressed before the survivin targeted therapies can be widely used in the clinics.
科研通智能强力驱动
Strongly Powered by AbleSci AI